2. Search Result
Search Result
Results for "

FcγRIIb

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

9

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99529
    Valziflocept

    BAX1810; TAK-752

    		 Fc Receptor (FcR) Inflammation/Immunology
    Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
    Valziflocept
  • HY-P99761
    Obexelimab

    XmAb5871

    		 CD19 Apoptosis Inflammation/Immunology
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
    Obexelimab
  • HY-P9950
    Omalizumab
    1 Publications Verification

    Olizumab; rhuMab-E25

    		 Interleukin Related Inflammation/Immunology Cancer
    Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
    Omalizumab
  • HY-P991086
    MGD010

    PRV-3279

    		 Fc Receptor (FcR) Inflammation/Immunology
    MGD010 is a bispecific CD32B (FcγRIIb) and CD79B antibody. MGD010 inhibits activated B-cells by delivering a negative signal via simultaneous co-ligation of CD32B (FcγRIIb), with the BCR component, CD79B. MGD010 has the potential for the study of autoimmune disorders .
    MGD010
  • HY-P991394
    SEA-TGT

    		Transmembrane Glycoprotein Cancer
    SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
    SEA-TGT
  • HY-P991582
    BI-1607

    		Fc Receptor (FcR) Cancer
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
    BI-1607
  • HY-P991525
    2141-V11

    		TNF Receptor Cancer
    2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer .
    2141-V11
  • HY-158316
    BTL-MK

    		Fc Receptor (FcR) Others
    BTL-MK (Compound 19) an orally active antiallergic agent, that inhibits degranulation of mast cells with an IC50 of 6.7 μM, through binding to the inhibitory receptor FcγRIIB. BTL-MK improves the metaboilic stability in human liver microsomes. BTL-MK ameliorates the allergic response in Ovalbumins (HY-W250978)-induced food allergy mice model. BTL-MK exhibits a good pharmacokinetic character with metabolic stability .
    BTL-MK
  • HY-P991070
    ADG-106

    		TNF Receptor Cancer
    ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    ADG-106
  • HY-P991225
    BI-1206

    		Fc Receptor (FcR) CD20 Inflammation/Immunology Cancer
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
    BI-1206

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: